Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome Therapies Utilizing Human-First Discovery Platform
Shots:
- Finch and Takeda will leverage Finch’s platform to develop microbiome-based therapeutics targeting Crohn’s disease. Takeda to get exclusive worldwide rights to commercialize rationally selected microbiota (RSM) therapies developed for Crohn’s disease
- In 2107- Takeda and Finch collaborated to jointly develop FIN-524 for ulcerative colitis under which Finch has received $10M upfront- milestones & royalties on global sales while Takeda got exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in IBD
- Finch’s human-first discovery platform allows the development of full-spectrum microbiota (FSM) therapies comprising a diverse community of microbiota from human donors as well as RSM therapies containing select bacterial strains- grown in pure culture in human microbiota transplantation studies
Click here to read full press release/ article | Ref: Businesswire | Image: Hines
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
